Share-based Payment Arrangement, Expense in USD of Context Therapeutics Inc. from Q2 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Context Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q2 2021 to Q3 2025.
  • Context Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $323K, a 51.7% increase year-over-year.
  • Context Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1.24M, a 42.9% increase year-over-year.
  • Context Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $842K, a 21.8% decline from 2023.
  • Context Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.08M, a 10.3% increase from 2022.
  • Context Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $976K, a 104% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Context Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.24M $323K +$110K +51.7% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 $1.13M $389K +$232K +148% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025
Q1 2025 $896K $294K +$53.7K +22.4% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $842K $232K -$24.2K -9.46% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025
Q3 2024 $866K $213K -$41.9K -16.5% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 $908K $157K -$126K -44.5% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025
Q1 2024 $1.03M $240K -$42.8K -15.1% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 $1.08M $256K +$12.4K +5.1% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 $1.06M $255K -$21.6K -7.8% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 $1.09M $283K +$41.8K +17.3% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 $1.04M $283K +$67.8K +31.5% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 $976K $244K 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024
Q3 2022 $277K +$125K +83% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $241K +$133K +122% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $215K 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q3 2021 $151K 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 $108K 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022

Context Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $842K -$235K -21.8% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025
2023 $1.08M +$100K +10.3% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025
2022 $976K +$499K +104% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024
2021 $478K 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.